Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Cyclophosphamide vs CNI for aGVHD Prevention After gDLI
NCT06490562Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jul 2024
- Primary completion
- May 2028
- Modality
- Small Molecules
01
Overview
Randomised, open-label trial of cyclophosphamide in Acute Graft-Versus-Host Disease (aGvHD) (2 arms), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Cumulative incidence of severe (III-IV) acute Graft-versus-host Disease. Planned start Jul 2024; status: not yet recruiting.
02
Drugs
cyclophosphamide
03
Conditions
Acute Graft-Versus-Host Disease (aGvHD)
Beyond the preview
Go deeper on NCT06490562.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06490562.